Stocks · News reference

8-K filing — ENANTA PHARMACEUTICALS INC (ENTA)

Jul 2, 2026, 8:56 PMSEC EDGAR

Filed: 2026-07-02 AccNo: 0001193125-26-294837 Size: 426 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ENTA

Source: edgar
Observed: Jul 2, 2026, 8:56 PM
Checked: Jul 2, 2026, 8:56 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 10, 2026, 8:05 PMBenzinga Newsdesk
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from
Read original at benzinga
ENTA
BenzingaJul 2, 2026, 8:58 PMBenzinga Newsdesk
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
Read original at benzinga
ENTA
BenzingaJun 23, 2026, 3:32 PMBenzinga Newsdesk
'Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral' - Bloomberg
Read original at benzinga
ENTA PFE

8-K filing — ENANTA PHARMACEUTICALS INC (ENTA)

Connected markets

Related headlines

Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate

Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies

'Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral' - Bloomberg